Apellis Pharmaceuticals

Expanded Labels And Complement Pipeline Will Capture Global Aging Markets

AnalystHighTarget

Not Invested

Consensus Narrative from 18 Analysts

Published

25 Aug 25

Updated

25 Aug 25

AnalystHighTarget's Fair Value

US$60.00

53.5% undervalued

25 Aug

US$27.93

-29.5%

4.7%

-29.5%

4.7%

Author's Valuation

US$60.0

53.5% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

US$60.0

53.5% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

14.47%

Biotech revenue growth rate

11.84%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.86%

Calculation

US$1.68b

Earnings '28

5.76x

PE Ratio '28

US$9.66b

Market Cap '28

US$9.66b

Market Cap '28

132.16m

No. shares '28

US$73.12

Share Price '28

US$73.12 Share Price '28

Discounted to 2025 @ 6.86% p.a.

US$59.93

Fair Value '25